George L. Bakris

Pennsylvania State System of Higher Education

Also affiliated with University of Mississippi, University of Chicago

MedicineNursing

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 29 papers. Top paper: “The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease”.

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Nephrology Dialysis Transplantation(2023)10.1093/ndt/gfad009

N/A

5.2DataRank · unranked

239 citations

Florian M.M. Baeres, George L. Bakris, Heidrun Bosch‐Traberg, Mette Gislum, Stephen Gough +9 more

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

Kidney International Reports(2021)10.1016/j.ekir.2021.10.008

N/A

4.8DataRank · unranked

165 citations

Gerasimos Filippatos, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luís M. Ruilope +10 more

Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus

Diabetes Care(2023)10.2337/dci23-0036

N/A

4.5DataRank · unranked

295 citations

Mark A. Arnold, George L. Bakris, David E. Bruns, Andrea R. Horvath, Åke Lernmark +4 more

Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria

Clinical Journal of the American Society of Nephrology(2021)10.2215/cjn.15260920

N/A

3.4DataRank · unranked

54 citations

Zien Zhou, Hiddo J.L. Heerspink, Carinna Hockham, Qiang Li, Rajiv Agarwal +18 more

Recognition and management of masked hypertension: A review and novel approach

Journal of the American Society of Hypertension(2013)10.1016/j.jash.2013.02.002

N/A

2.2DataRank · unranked

40 citations

George L. Bakris, Yuichiro Yano

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes

Hypertension(2022)10.1161/hypertensionaha.122.19744

N/A

2.1DataRank · unranked

98 citations

Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing +8 more

A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease

Clinical Kidney Journal(2022)10.1093/ckj/sfac234

N/A

2.0DataRank · unranked

102 citations

Bertram Pitt, Biff F. Palmer, Csaba P. Kövesdy, Ellen Burgess, Gerasimos Filippatos +12 more

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results

Nephrology Dialysis Transplantation(2021)10.1093/ndt/gfab336

N/A

1.7DataRank · unranked

62 citations

Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luís M. Ruilope +12 more

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Hypertension(2003)10.1161/01.hyp.0000107251.49515.c2

N/A

1.4DataRank · unranked

13259 citations

George L. Bakris, Henry R. Black, William C. Cushman, Lee A. Green, Joseph L. Izzo +7 more

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis

European Heart Journal - Cardiovascular Pharmacotherapy(2023)10.1093/ehjcvp/pvad001

N/A

1.3DataRank · unranked

39 citations

Stefan D. Anker, Phyllis August, Andrew J.S. Coats, James L. Januzzi, Boris Mankovsky +13 more

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Diabetes Care(2022)10.2337/dc21-1944

N/A

1.2DataRank · unranked

35 citations

Ellen Burgess, Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt +92 more

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

Nephrology Dialysis Transplantation(2024)10.1093/ndt/gfae132

N/A

0.661DataRank · unranked

81 citations

Rajiv Agarwal, George L. Bakris, David Z.I. Cherney, Carolyn S.P. Lam, Brendon L. Neuen +95 more

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Journal of the American Heart Association(2022)10.1161/jaha.121.025045

N/A

0.578DataRank · unranked

10 citations

Clare Arnott, Hiddo J.L. Heerspink, Qiang Li MBiostat, Christopher P. Cannon, David C. Wheeler +16 more

Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone

JAMA Cardiology(2023)10.1001/jamacardio.2023.1505

N/A

0.538DataRank · unranked

35 citations

Bertram Pitt, Peter Rossing, Stefan D. Anker, Gerasimos Filippatos, Luís M. Ruilope +10 more

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

Journal of the American Heart Association(2023)10.1161/jaha.122.028516

N/A

0.459DataRank · unranked

7 citations

Clare Arnott, Patrick Rockenschaub, Aletta E. Schutte, Lewis Carpenter, Muthiah Vaduganathan +13 more

Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure

JACC Heart Failure(2022)10.1016/j.jchf.2022.03.004

N/A

0.434DataRank · unranked

17 citations

Jeroen V. Koomen, Donald E. Kohan, John J.V. McMurray, George L. Bakris, Ricardo Correa‐Rotter +11 more

Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus

Clinical Chemistry(2023)10.1093/clinchem/hvad079

N/A

0.345DataRank · unranked

9 citations

Mark A. Arnold, George L. Bakris, David E. Bruns, Andrea R. Horvath, Åke Lernmark +4 more

Newer alternatives for resistant hypertension: Beyond 2022 paradigms

Hellenic Journal of Cardiology(2023)10.1016/j.hjc.2023.01.006

N/A

0DataRank · unranked

2 citations

Αlexandros Briasoulis, George L. Bakris, Luke J. Laffin

Key questions regarding the SYMPLICITY HTN-3 trial – Authors' reply

The Lancet(2023)10.1016/s0140-6736(23)00337-9

N/A

0DataRank · unranked

0 citations

George L. Bakris, Deepak L. Bhatt

Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease

American Journal of Hypertension(2024)10.1093/ajh/hpae020

N/A

0DataRank · unranked

5 citations

Cindy Chen, Alicia K. Campbell, Veronica Ashton, Lloyd Haskell, Mukul Singhal +1 more

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)

Nephrology Dialysis Transplantation(2022)10.1093/ndt/gfac198

N/A

0DataRank · unranked

160 citations

Amy K. Mottl, George L. Bakris, Hiddo J.L. Heerspink, Johannes F.E. Mann, Janet B. McGill +6 more

Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

Kidney International(2020)10.1016/j.kint.2020.10.031

N/A

0DataRank · unranked

212 citations

Matthew R. Weir, George L. Bakris, Michaela Mattheus, David Z.I. Cherney, Naveed Sattar +8 more

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

European Heart Journal(2021)10.1093/eurheartj/ehab777

N/A

0DataRank · unranked

1207 citations

Gerasimos Filippatos, Bertram Pitt, Stefan D. Anker, Peter Rossing, Amer Joseph +7 more

Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus

American Heart Journal(2020)10.1016/j.ahj.2020.07.014

N/A

0DataRank · unranked

8 citations

Abhinav Sharma, William B. White, George L. Bakris, Patrick Rossignol, Cyrus R. Mehta +3 more

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Circulation(2023)10.1161/circulationaha.123.067584

N/A

0DataRank · unranked

312 citations

Hiddo J.L. Heerspink, Priya Vart, Brian Claggett, Robert A. Fletcher, Clare Arnott +11 more

Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

Diabetes Obesity and Metabolism(2020)10.1111/dom.14252

N/A

0DataRank · unranked

21 citations

Jasper Stevens, George L. Bakris, Ricardo Correa‐Rotter, Fan Fan Hou, Dalane W. Kitzman +9 more

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Kidney International(2020)10.1016/j.kint.2020.10.042

N/A

0DataRank · unranked

160 citations

Meg Jardine, Rajiv Agarwal, George L. Bakris, Christopher P. Cannon, David M. Charytan +15 more

Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus

Clinical Chemistry(2023)10.1093/clinchem/hvad080

N/A

0DataRank · unranked

127 citations

Mark A. Arnold, George L. Bakris, David E. Bruns, Andrea R. Horvath, Åke Lernmark +4 more

Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial

The Lancet Diabetes & Endocrinology(2023)10.1016/s2213-8587(23)00291-7

N/A

0DataRank · unranked

5 citations

Stefan D. Anker, Javed Butler, George L. Bakris, Deepak L. Bhatt, Gregg C. Fonarow +2 more